Skip to content

 

Newsroom

Newsroom

  • August 6, 2019 - Vertos Medical Appoints New Vice President of Sales
    Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced the appointment of Stephen E. Paul as Vice President of Sales. Mr. Paul will be responsible for directing all aspects of sales for the U.S. commercial expansion.
  • February 26, 2019 - Vertos mild Procedure Cleared for European Use
    Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), announced today that it received CE mark approval for its mild device kit. This certification signifies that Vertos has conformed to patient and user safety and device performance standards for the mild device kit and procedure to be marketed and sold in the 32 countries of the European Economic Area.
  • September 11, 2018 - Vertos Medical Announces mild Procedure Long-term Safety and Efficacy Data
    Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced the publication of two-year data from a Centers for Medicare & Medicaid Services (CMS)-approved study, MiDAS ENCORE. The data affirms long-term safety and efficacy of the mild lumbar decompression procedure, a clinically proven outpatient procedure that removes the cause of the stenosis through a portal the size of a baby aspirin and requires no implants, no general anesthesia, no stitches, and no overnight hospital stay.
  • October 24, 2017 - Vertos Medical Wins This Year's OCTANe High Tech Innovation Awards For Its Unique Medical Technology
    Vertos Medical, a medical device company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis, won the 'Medtech' category at this year's 2017 High Tech Innovation Awards by OCTANe for its mild procedure technology. mild is an FDA-cleared procedure that has been used to treat lumbar spinal stenosis (LSS) in more than 20,000 patients in the United States. Its high safety and efficacy have been demonstrated in more than 12 clinical studies.
  • June 12, 2017 - Vertos Medical Secures $28 Million In Latest Round Of Funding
    Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis (LSS), announced today it has completed a $28 million financing round. New investor, MVM Life Science Partners LLP, led the round with participation from existing investors Leerink Revelation Partners, Pitango Venture Capital, ONSET Ventures, and Aweida Venture Partners. Proceeds of the financing will be used to expand commercialization of the company's proprietary mild procedure, a clinically proven outpatient procedure that removes the cause of the stenosis through a portal the size of a baby aspirin and requires no implants, no general anesthesia, no stitches, and no overnight hospital stay.
  • March 7, 2017 - Vertos Medical's mild Procedure Receives Broad Coverage From Centers for Medicare & Medicaid Services
    Vertos Medical, a medical device company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), has received national coverage for its mild Procedure through a recently approved study under the Centers for Medicare & Medicaid Services' (CMS) Coverage with Evidence Development (CED) Program. A clinically proven outpatient procedure performed through a portal the size of a baby aspirin, mild requires no stitches, no general anesthesia, no implants, and no overnight hospital stay.